176 related articles for article (PubMed ID: 20142246)
1. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study.
Mucci LA; Stark JR; Pollak MN; Li H; Kurth T; Stampfer MJ; Ma J
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):484-91. PubMed ID: 20142246
[TBL] [Abstract][Full Text] [Related]
2. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer.
Ma C; Wang Y; Wilson KM; Mucci LA; Stampfer MJ; Pollak M; Penney KL
JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35047751
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E
J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
[TBL] [Abstract][Full Text] [Related]
5. Association of umbilical cord plasma acid-labile subunit of the insulin-like growth factor ternary complex with anthropometry in term newborns.
Tseng YM; Hwang YS; Lu CL; Lin SJ; Tsai WH
Pediatr Neonatol; 2014 Apr; 55(2):139-44. PubMed ID: 24211220
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.
Allen NE; Key TJ; Appleby PN; Travis RC; Roddam AW; Rinaldi S; Egevad L; Rohrmann S; Linseisen J; Pischon T; Boeing H; Johnsen NF; Tjønneland A; Grønbaek H; Overvad K; Kiemeney L; Bueno-de-Mesquita HB; Bingham S; Khaw KT; Tumino R; Berrino F; Mattiello A; Sacerdote C; Palli D; Quirós JR; Ardanaz E; Navarro C; Larrañaga N; Gonzalez C; Sanchez MJ; Trichopoulou A; Travezea C; Trichopoulos D; Jenab M; Ferrari P; Riboli E; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1121-7. PubMed ID: 17548673
[TBL] [Abstract][Full Text] [Related]
8. IGF-I, IGF-II, IGFBP2, IGFBP3 and acid-labile subunit (ALS) in colorectal cancer patients before surgery and during one year follow up in relation to age.
Sztefko K; Hodorowicz-Zaniewska D; Popiela T; Richter P
Adv Med Sci; 2009; 54(1):51-8. PubMed ID: 19482725
[TBL] [Abstract][Full Text] [Related]
9. The acid-labile subunit of the ternary insulin-like growth factor complex in cirrhosis: relation to liver dysfunction.
Møller S; Juul A; Becker U; Henriksen JH
J Hepatol; 2000 Mar; 32(3):441-6. PubMed ID: 10735614
[TBL] [Abstract][Full Text] [Related]
10. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
[TBL] [Abstract][Full Text] [Related]
11. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
[TBL] [Abstract][Full Text] [Related]
12. Acid-labile subunit in growth hormone excess and deficiency in adults: evaluation of its diagnostic value in comparison with insulin-like growth factor (IGF)-I and IGF-binding protein-3.
Fukuda I; Hizuka N; Itoh E; Yasumoto K; Ishikawa Y; Murakami Y; Sata A; Takano K
Endocr J; 2002 Jun; 49(3):379-86. PubMed ID: 12201224
[TBL] [Abstract][Full Text] [Related]
13. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
14. Primary acid-labile subunit deficiency due to recessive IGFALS mutations results in postnatal growth deficit associated with low circulating insulin growth factor (IGF)-I, IGF binding protein-3 levels, and hyperinsulinemia.
Heath KE; Argente J; Barrios V; Pozo J; Díaz-González F; Martos-Moreno GA; Caimari M; Gracia R; Campos-Barros A
J Clin Endocrinol Metab; 2008 May; 93(5):1616-24. PubMed ID: 18303074
[TBL] [Abstract][Full Text] [Related]
15. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.
Cao Y; Nimptsch K; Shui IM; Platz EA; Wu K; Pollak MN; Kenfield SA; Stampfer MJ; Giovannucci EL
Int J Cancer; 2015 May; 136(10):2418-26. PubMed ID: 25348852
[TBL] [Abstract][Full Text] [Related]
16. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
[TBL] [Abstract][Full Text] [Related]
19. Common genetic variation of insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, and acid labile subunit in relation to serum IGF-I levels and mammographic density.
Taverne CW; Verheus M; McKay JD; Kaaks R; Canzian F; Grobbee DE; Peeters PH; van Gils CH
Breast Cancer Res Treat; 2010 Oct; 123(3):843-55. PubMed ID: 20155489
[TBL] [Abstract][Full Text] [Related]
20. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.
Gu F; Schumacher FR; Canzian F; Allen NE; Albanes D; Berg CD; Berndt SI; Boeing H; Bueno-de-Mesquita HB; Buring JE; Chabbert-Buffet N; Chanock SJ; Clavel-Chapelon F; Dumeaux V; Gaziano JM; Giovannucci EL; Haiman CA; Hankinson SE; Hayes RB; Henderson BE; Hunter DJ; Hoover RN; Johansson M; Key TJ; Khaw KT; Kolonel LN; Lagiou P; Lee IM; LeMarchand L; Lund E; Ma J; Onland-Moret NC; Overvad K; Rodriguez L; Sacerdote C; Sánchez MJ; Stampfer MJ; Stattin P; Stram DO; Thomas G; Thun MJ; Tjønneland A; Trichopoulos D; Tumino R; Virtamo J; Weinstein SJ; Willett WC; Yeager M; Zhang SM; Kaaks R; Riboli E; Ziegler RG; Kraft P
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2877-87. PubMed ID: 20810604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
